CNA – Britain’s medicines regulator has approved AstraZeneca’s antibody-based COVID-19 treatment for adults with poor immune response, marking a major step in the fight against the pandemic as infections surge globally amid the spread of the Omicron variant. More details in Friday’s Borneo Bulletin.
